A new treatment to prevent complications in dialysis access for kidney patients
Official title: Contact Pathway Inhibitor to Prevent Vascular Access Failure
Funded at Aronora, INC. · NIH-10954345 · Data updated 2026-11-12
This study is testing a new medication called AB023 to see if it can help improve the success and lifespan of the grafts used for dialysis in patients with kidney disease, especially focusing on helping Black patients who often face more challenges with these procedures.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aronora, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,480,856 |
| NIH project number | 4R44HL167467-02 |
| Project ID | NIH-10954345 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with end-stage renal disease who are currently using arteriovenous grafts for hemodialysis.
✕Less likely to help
Patients who do not require hemodialysis or those using arteriovenous fistulas instead of grafts may not benefit from this research.
What this research studies
This research focuses on developing a novel antithrombotic agent, AB023 (xisomab 3G3), aimed at improving the longevity and effectiveness of arteriovenous grafts (AVGs) used in patients with end-stage renal disease (ESRD) who require hemodialysis. The study addresses significant healthcare disparities, particularly among Black/African American patients, by targeting the high rates of AVG use and associated complications. By evaluating the safety and efficacy of this treatment in a clinical trial, the research seeks to enhance patient outcomes and reduce the risk of vascular access failure.
Why it matters
Potential benefit: If successful, this research could significantly improve the durability of dialysis access for patients, leading to better health outcomes and quality of life.
How similar studies have gone: Previous research has shown promise in using antithrombotic agents for improving vascular access outcomes, making this approach both relevant and potentially impactful.
Where this research is happening
-
Aronora, INC.
Portland, United States Active
Researchers
- Principal investigator: Lorentz, Christina U — Aronora, INC.
- Study coordinator: Lorentz, Christina U
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.